Evaluation of Acute and Early Cardiotoxicity in Survivors of Hodgkin's Disease Treated with ABVD or BEACOPP Regimens

References

• Diehl V, Thomas RT, Re D. Hodgkin's lymphoma-diag-nosis and treatment. Lancet 2004; 5: 19–26
   PubMed Web of Science ®Google Scholar
• Glossmann JP, Jostig A, Diehl V. New treatments for Hodgkin's disease. Curr Treat Option Oncol 2002; 3: 283–290
   PubMedGoogle Scholar
• Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 27: 1949–1955
   Google Scholar
• Adams JM, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139–3148
   PubMed Web of Science ®Google Scholar
• Krupicka J, Markova J, Pohlereich D, Kozak T, Linkova H, Diehl V. Echocardiographic evaluation of acute cardiotoxic-ity in the treatment of Hodgkin's disease according to the German Hodgkin's Lymphoma Study Group. Leukemia & Lymphoma 2002; 43: 2325–2329
   PubMed Web of Science ®Google Scholar
• Brice P, Tredaniel J, Monsuez JJ, et al. Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's disease. Annals Oncol 1991; 2: 73–76
   PubMed Web of Science ®Google Scholar
• LaMonte ChS, Samuel DJ, Straus DJ. Long-term follow-up of cardiac function in patients with Hodgkin's disease treat-ed with mediastinal irradiation and combination chemotherapy including doxorubicin. Cancer Treat Rep 1986; 70: 439–444
   PubMedGoogle Scholar
• Aviles A, Arevila N, Diaz Maqueo JC, Gomez T, Garcia R, Jesus Nambo MA. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. Leukemia & Lymphoma 1993; 11: 275–276
   PubMed Web of Science ®Google Scholar
• Kreuser AD, Voller H, Behles Ch, et al. Evaluation of late cardiotoxicity with pulsed Doppler echocardiography in patients treated for Hodgkin's disease. Brit J Hematol 1993; 84: 615–622
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a Committee Convened to Discuss the Evaluation and Staging of Patients with Hodgkin's Disease: Costworlds Meeting. J Clin Oncol 1989; 7: 1630–1635
   PubMed Web of Science ®Google Scholar
• Otto CM. Echocardiographic evaluation of left and right ventricular systolic function. In: Otto CM. Textbook of clinical echocardiography. 2nd ed. Philadelphia, WB Saunders Comp, 2000: 100-131
   Google Scholar
• Tei Ch, Lieng H, Hodge DO, et al. New index of com-bined systolic and diastolic myocardial performance: A simple and reproducible measure of cardiac function-A study in nor-mals and dilated cardiomyopathy. J Cardiol 1995; 26: 357–366
   PubMedGoogle Scholar
• Beck KC, Weisman IM. Methods for cardiopulmonary exercise testing. In: Weisman IM, Zeballos RJ. Clinical exer-cise testing. Prog Respir Res. Basel, Karger, 2002, vol. 32, pp 43–59
   Google Scholar
• Picano E. Stress Echocardiography. 3rd ed. Springer-Verlag Berlin Heidelberg New York, 1997: 1-305
   Google Scholar
• Green DM, Gingell RL, Pearce J, Panahon AM, Ghoorah J. The effect of mediastinal irradiation on cardiac function of patients treated during childhood and adolescence for Hodgkin's disease. J Clin Oncol 1987; 5: 239–245
   PubMed Web of Science ®Google Scholar
• Singal P, Iliskovic N. Current concepts: doxorubicin-induced cardiotoxicity. N Engl J Med 1998; 339: 900–905
   PubMed Web of Science ®Google Scholar
• Watts RG. Severe and fatal anthracycline cardiotoxicity at cumulative doses below 400mg/m2. Am J Hematol, 1991; 36: 217–217
   PubMed Web of Science ®Google Scholar
• Lund MB, Kongerud J, Boe J, et al. Cardiopulmonary sequelae after treatment for Hodgkin's disease: Increased risk in females? Annals Oncol 1996; 7: 257–264
   PubMed Web of Science ®Google Scholar
• Morgan GW, Freeman AP, McLean RG, et al. Late car-diac thyroid and pulmonary sequelae of mantle radiotherapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1985; 11: 1925–1931
   PubMed Web of Science ®Google Scholar
• Hancock SL, Donaldson SS, Hoppe RT. Cardiac Disease Following Treatment of Hodgkin's Disease in Children and Adolescents. J Clin Oncol 1993; 11: 1208–1215
   PubMed Web of Science ®Google Scholar
• Sarialioglu II, Ozbarlas N, Buyukpamukcu M, Akyuz C, Tutluk T. Late cardiac effects after treatment for childhood Hodgkin's disease with chemotherapy and low-dose radiother-apy. Postgrad Med J 1995; 71: 164–167
   PubMed Web of Science ®Google Scholar
• Cameron EH, Lipshultz SE, Tarbell NJ, Mauch PM. Cardiovascular disease in long-term survivors of pediatric Hodgkin's disease. Progress Pediatr Cardiol 1998; 8: 139–144
   Web of Science ®Google Scholar
• Bu'Lock FA, Mot MG, Oakhill A, Martin RP. Left ven-tricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J 1995; 73: 340–350
   Google Scholar
• Ewer MS, Ali MK, Gibbs HR, et al. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol 1994; 33: 645–649
   PubMed Web of Science ®Google Scholar
• Ruffer JU, Flechtner H, Trails P, et al. Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 2003; 39: 2179–2186
   PubMed Web of Science ®Google Scholar
• Ho-a---y ny AN, Silber JF, Paridon SM. Cardiopulmonary exercise testing in evaluation of the functional capacity of sur-vivors of childhood cancer. Progress Pediatr Cardiol 1998; 8: 109–119
   Google Scholar
• Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749–2754
   PubMed Web of Science ®Google Scholar
• Specchia G, Buquicchio C, Pansini N, et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med 2005; 145: 212–220
   PubMed Web of Science ®Google Scholar
• Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005; 51: 1405-1410
   Google Scholar